

# Paolo Vicini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11750077/publications.pdf>

Version: 2024-02-01

94  
papers

3,438  
citations

147566

31  
h-index

155451

55  
g-index

97  
all docs

97  
docs citations

97  
times ranked

4216  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 148-163.	2.3	60
2	A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade. <i>Scientific Reports</i> , 2019, 9, 11286.	1.6	69
3	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	2.2	53
4	<i>in silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. <i>Royal Society Open Science</i> , 2019, 6, 190366.	1.1	54
5	Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. <i>Clinical and Translational Science</i> , 2019, 12, 450-458.	1.5	13
6	Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 259-272.	1.3	37
7	Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 631-642.	2.3	111
8	Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 826-835.	2.3	6
9	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 649.	1.3	30
10	Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly. <i>Nature Communications</i> , 2017, 8, 1026.	5.8	24
11	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170320.	1.5	118
12	Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. <i>Clinical Cancer Research</i> , 2017, 23, 1080-1090.	3.2	26
13	Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success. <i>Annals of Biomedical Engineering</i> , 2016, 44, 2626-2641.	1.3	66
14	Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 230-236.	0.7	12
15	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 253-265.	1.5	10
16	Multiscale Modeling in the Clinic: Drug Design and Development. <i>Annals of Biomedical Engineering</i> , 2016, 44, 2591-2610.	1.3	50
17	Application of Quantitative Biomeasures in Early Drug Discovery. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 37-46.	0.2	0
18	Organ Dose Estimates for Hyperthyroid Patients Treated with 131I: An Update of the Thyrotoxicosis Follow-Up Study. <i>Radiation Research</i> , 2015, 184, 595.	0.7	22

#	ARTICLE	IF	CITATIONS
19	The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	0.9	18
20	Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. <i>Cellular Immunology</i> , 2015, 295, 118-126.	1.4	68
21	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 67-75.	1.1	13
22	Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase. <i>Drug Metabolism and Disposition</i> , 2015, 43, 54-62.	1.7	21
23	A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations. <i>Blood</i> , 2015, 126, 3502-3502.	0.6	1
24	Bloodâ€“Tissue Exchange Modelling. , 2014, , 381-415.		0
25	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 67-76.	1.3	27
26	A review of quantitative modeling of B cell responses to antigenic challenge. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 445-459.	0.8	2
27	Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies. <i>AAPS Journal</i> , 2013, 15, 551-558.	2.2	20
28	A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics. <i>AAPS Journal</i> , 2013, 15, 1141-1154.	2.2	41
29	Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1285-1294.	1.7	24
30	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentrationâ€“Time Curve in Hematopoietic Cell Transplantation Recipients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1654-1664.	1.0	17
31	The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 932-939.	1.1	25
32	Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 549-557.	1.3	62
33	Ketorolac tromethamine: stereoâ€“specific pharmacokinetics and singleâ€“dose use in postoperative infants aged 2â€“6 months. <i>Paediatric Anaesthesia</i> , 2011, 21, 325-334.	0.6	37
34	Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 964-973.	1.3	29
35	An Approach to Determining Intracranial Pressure Variability Capable of Predicting Decreased Intracranial Adaptive Capacity in Patients With Traumatic Brain Injury. <i>Biological Research for Nursing</i> , 2010, 11, 317-324.	1.0	16
36	Measurement of Human Surfactant Protein-B Turnover in Vivo from Tracheal Aspirates Using Targeted Proteomics. <i>Analytical Chemistry</i> , 2010, 82, 2561-2567.	3.2	19

#	ARTICLE	IF	CITATIONS
37	IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E950-E960.	1.8	19
38	Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Pharmacology, 2009, 49, 88-102.	1.0	34
39	A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clinical Cancer Research, 2009, 15, 5280-5287.	3.2	22
40	Nonlinear Mixed Effects to Improve Glucose Minimal Model Parameter Estimation: A Simulation Study in Intensive and Sparse Sampling. IEEE Transactions on Biomedical Engineering, 2009, 56, 2156-2166.	2.5	14
41	The System for Population Kinetics. , 2009, , 556-571.		0
42	Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus. Metabolism: Clinical and Experimental, 2008, 57, 445-447.	1.5	3
43	Glucose Minimal Model population analysis: Likelihood function profiling via Monte Carlo sampling. , 2008, 2008, 4932-5.		3
44	Kinetic Modeling in Support of Radionuclide Dose Assessment. Seminars in Nuclear Medicine, 2008, 38, 335-346.	2.5	17
45	Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. , 2008, 2008, 5454-7.		17
46	Intracranial Pressure Waveform Morphology and Intracranial Adaptive Capacity. American Journal of Critical Care, 2008, 17, 545-554.	0.8	50
47	Intracranial pressure waveform morphology and intracranial adaptive capacity. American Journal of Critical Care, 2008, 17, 545-54.	0.8	18
48	Postoperative Ketorolac Tromethamine Use in Infants Aged 6-18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics. Anesthesia and Analgesia, 2007, 104, 1040-1051.	1.1	41
49	Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition. Clinical Cancer Research, 2007, 13, 4271-4279.	3.2	64
50	Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 595-621.	0.8	10
51	Kinetic Modeling of Contrast-Enhanced MRI: An Automated Technique for Assessing Inflammation in the Rheumatoid Arthritis Wrist. Annals of Biomedical Engineering, 2007, 35, 781-795.	1.3	13
52	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. , 2006, 2006, 5049-52.		4
53	Catch-Bond Model Derived from Allostery Explains Force-Activated Bacterial Adhesion. Biophysical Journal, 2006, 90, 753-764.	0.2	176
54	THE GLUCOSE MINIMAL MODEL: POPULATION VS INDIVIDUAL PARAMETER ESTIMATION. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 231-235.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Computer Simulations in Pharmacokinetics and Pharmacodynamics: Rediscovering Systems Physiology in the 21st Century. , 2006, , 513-528.		0
56	A Fuzzy Physiologically Based Pharmacokinetic Modeling Framework to Predict Drug Disposition in Humans. , 2006, 2006, 5037-40.		1
57	Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach. Clinical Cancer Research, 2006, 12, 4888-4898.	3.2	40
58	Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E716-E723.	1.8	17
59	A Fuzzy Physiologically Based Pharmacokinetic Modeling Framework to Predict Drug Disposition in Humans. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
60	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
61	Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clinical Pharmacology and Therapeutics, 2005, 78, 298-308.	2.3	31
62	Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. AAPS Journal, 2005, 7, E759-E785.	2.2	32
63	Estimating in Vitro Mitochondrial Oxygen Consumption During Muscle Contraction and Recovery: A Novel Approach that Accounts for Diffusion. Annals of Biomedical Engineering, 2005, 33, 343-355.	1.3	4
64	Robust Population Pharmacokinetic Experiment Design. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 33-64.	0.8	42
65	Integrated model of hepatic and peripheral glucose regulation for estimation of endogenous glucose production during the hot IVGTT. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1038-E1046.	1.8	26
66	Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo- $\alpha$ -Acetylmethadol. Clinical Pharmacokinetics, 2005, 44, 731-751.	1.6	13
67	Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors. Clinical Cancer Research, 2004, 10, 8048-8058.	3.2	46
68	Pubertal changes in HOMA and QUICKI: relationship to hepatic and peripheral insulin sensitivity. Pediatric Diabetes, 2004, 5, 122-125.	1.2	18
69	poped, a software for optimal experiment design in population kinetics. Computer Methods and Programs in Biomedicine, 2004, 74, 29-46.	2.6	79
70	Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramidate mustard. Clinical Pharmacology and Therapeutics, 2004, 76, 270-280.	2.3	20
71	Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart and Human Insulin. Journal of Pharmacokinetics and Pharmacodynamics, 2003, 30, 221-235.	0.8	30
72	An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations. Annals of Biomedical Engineering, 2003, 31, 98-111.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 19, 141-150.	1.9	59
74	Quantitative Magnetic Resonance Imaging Analysis of Neovasculature Volume in Carotid Atherosclerotic Plaque. <i>Circulation</i> , 2003, 107, 851-856.	1.6	340
75	Epinephrine effects on insulin-glucose dynamics: the labeled IVGTT two-compartment minimal model approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E78-E84.	1.8	19
76	Model-based Approaches to Biomarker Discovery and Evaluation: A Multidisciplinary Integrated Review. <i>Critical Reviews in Biomedical Engineering</i> , 2002, 30, 349-418.	0.5	8
77	The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 280, E179-E186.	1.8	42
78	Blood-Tissue Exchange Modelling. , 2001, , 373-401.		0
79	An Evaluation of Extended vs Weighted Least Squares for Parameter Estimation in Physiological Modeling. <i>Journal of Biomedical Informatics</i> , 2001, 34, 348-364.	2.5	13
80	Cellular energetics analysis by a mathematical model of energy balance: estimation of parameters in human skeletal muscle. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 279, C213-C224.	2.1	50
81	Pubertal Adolescent Male-Female Differences in Insulin Sensitivity and Glucose Effectiveness Determined by the One Compartment Minimal Model. <i>Pediatric Research</i> , 2000, 48, 384-388.	1.1	105
82	Identifiability and interval identifiability of mammillary and catenary compartmental models with some known rate constants. <i>Mathematical Biosciences</i> , 2000, 167, 145-161.	0.9	6
83	Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 276, E285-E294.	1.8	22
84	Individual Prior Information in a Physiological Model of 2H8-Toluene Kinetics: An Empirical Bayes Estimation Strategy. <i>Risk Analysis</i> , 1999, 19, 1127-1134.	1.5	7
85	A Priori Identifiability of Distributed Models of Blood-Tissue Exchange. <i>Annals of Biomedical Engineering</i> , 1999, 27, 200-207.	1.3	8
86	Estimation of Blood Flow Heterogeneity in Human Skeletal Muscle Using Intravascular Tracer Data: Importance for Modeling Transcapillary Exchange. <i>Annals of Biomedical Engineering</i> , 1998, 26, 764-774.	1.3	14
87	A Pharmacokinetic/Pharmacodynamic Comparison of SAAM II and PC/WinNonlin Modeling Software. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1255-1263.	1.6	34
88	Biological monitoring of controlled toluene exposure. <i>International Archives of Occupational and Environmental Health</i> , 1998, 71, 433-444.	1.1	35
89	SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 484-492.	1.5	401
90	Approaches to Population Kinetic Analysis with Application to Metabolic Studies. <i>Advances in Experimental Medicine and Biology</i> , 1998, 445, 103-113.	0.8	3

#	ARTICLE	IF	CITATIONS
91	The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E1024-E1032.	1.8	66
92	Estimation of endogenous glucose production after a glucose perturbation by nonparametric stochastic deconvolution. <i>Computer Methods and Programs in Biomedicine</i> , 1997, 52, 147-156.	2.6	23
93	Parameter estimation in distributed models of blood-tissue Exchange: A monte carlo strategy to assess precision. <i>Annals of Biomedical Engineering</i> , 1997, 25, 815-821.	1.3	6
94	Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. <i>Annals of Biomedical Engineering</i> , 1997, 25, 906-910.	1.3	29